Cargando…

Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study

OBJECTIVES: Being able to predict which patients with COVID-19 are going to deteriorate is important to help identify patients for clinical and research practice. Clinical prediction models play a critical role in this process, but current models are of limited value because they are typically restr...

Descripción completa

Detalles Bibliográficos
Autores principales: Berzuini, Carlo, Hannan, Cathal, King, Andrew, Vail, Andy, O'Leary, Claire, Brough, David, Galea, James, Ogungbenro, Kayode, Wright, Megan, Pathmanaban, Omar, Hulme, Sharon, Allan, Stuart, Bernardinelli, Luisa, Patel, Hiren C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513423/
https://www.ncbi.nlm.nih.gov/pubmed/32967887
http://dx.doi.org/10.1136/bmjopen-2020-041983
_version_ 1783586381216350208
author Berzuini, Carlo
Hannan, Cathal
King, Andrew
Vail, Andy
O'Leary, Claire
Brough, David
Galea, James
Ogungbenro, Kayode
Wright, Megan
Pathmanaban, Omar
Hulme, Sharon
Allan, Stuart
Bernardinelli, Luisa
Patel, Hiren C
author_facet Berzuini, Carlo
Hannan, Cathal
King, Andrew
Vail, Andy
O'Leary, Claire
Brough, David
Galea, James
Ogungbenro, Kayode
Wright, Megan
Pathmanaban, Omar
Hulme, Sharon
Allan, Stuart
Bernardinelli, Luisa
Patel, Hiren C
author_sort Berzuini, Carlo
collection PubMed
description OBJECTIVES: Being able to predict which patients with COVID-19 are going to deteriorate is important to help identify patients for clinical and research practice. Clinical prediction models play a critical role in this process, but current models are of limited value because they are typically restricted to baseline predictors and do not always use contemporary statistical methods. We sought to explore the benefits of incorporating dynamic changes in routinely measured biomarkers, non-linear effects and applying ‘state-of-the-art’ statistical methods in the development of a prognostic model to predict death in hospitalised patients with COVID-19. DESIGN: The data were analysed from admissions with COVID-19 to three hospital sites. Exploratory data analysis included a graphical approach to partial correlations. Dynamic biomarkers were considered up to 5 days following admission rather than depending solely on baseline or single time-point data. Marked departures from linear effects of covariates were identified by employing smoothing splines within a generalised additive modelling framework. SETTING: 3 secondary and tertiary level centres in Greater Manchester, the UK. PARTICIPANTS: 392 hospitalised patients with a diagnosis of COVID-19. RESULTS: 392 patients with a COVID-19 diagnosis were identified. Area under the receiver operating characteristic curve increased from 0.73 using admission data alone to 0.75 when also considering results of baseline blood samples and to 0.83 when considering dynamic values of routinely collected markers. There was clear non-linearity in the association of age with patient outcome. CONCLUSIONS: This study shows that clinical prediction models to predict death in hospitalised patients with COVID-19 can be improved by taking into account both non-linear effects in covariates such as age and dynamic changes in values of biomarkers.
format Online
Article
Text
id pubmed-7513423
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-75134232020-09-25 Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study Berzuini, Carlo Hannan, Cathal King, Andrew Vail, Andy O'Leary, Claire Brough, David Galea, James Ogungbenro, Kayode Wright, Megan Pathmanaban, Omar Hulme, Sharon Allan, Stuart Bernardinelli, Luisa Patel, Hiren C BMJ Open Research Methods OBJECTIVES: Being able to predict which patients with COVID-19 are going to deteriorate is important to help identify patients for clinical and research practice. Clinical prediction models play a critical role in this process, but current models are of limited value because they are typically restricted to baseline predictors and do not always use contemporary statistical methods. We sought to explore the benefits of incorporating dynamic changes in routinely measured biomarkers, non-linear effects and applying ‘state-of-the-art’ statistical methods in the development of a prognostic model to predict death in hospitalised patients with COVID-19. DESIGN: The data were analysed from admissions with COVID-19 to three hospital sites. Exploratory data analysis included a graphical approach to partial correlations. Dynamic biomarkers were considered up to 5 days following admission rather than depending solely on baseline or single time-point data. Marked departures from linear effects of covariates were identified by employing smoothing splines within a generalised additive modelling framework. SETTING: 3 secondary and tertiary level centres in Greater Manchester, the UK. PARTICIPANTS: 392 hospitalised patients with a diagnosis of COVID-19. RESULTS: 392 patients with a COVID-19 diagnosis were identified. Area under the receiver operating characteristic curve increased from 0.73 using admission data alone to 0.75 when also considering results of baseline blood samples and to 0.83 when considering dynamic values of routinely collected markers. There was clear non-linearity in the association of age with patient outcome. CONCLUSIONS: This study shows that clinical prediction models to predict death in hospitalised patients with COVID-19 can be improved by taking into account both non-linear effects in covariates such as age and dynamic changes in values of biomarkers. BMJ Publishing Group 2020-09-23 /pmc/articles/PMC7513423/ /pubmed/32967887 http://dx.doi.org/10.1136/bmjopen-2020-041983 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Methods
Berzuini, Carlo
Hannan, Cathal
King, Andrew
Vail, Andy
O'Leary, Claire
Brough, David
Galea, James
Ogungbenro, Kayode
Wright, Megan
Pathmanaban, Omar
Hulme, Sharon
Allan, Stuart
Bernardinelli, Luisa
Patel, Hiren C
Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study
title Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study
title_full Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study
title_fullStr Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study
title_full_unstemmed Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study
title_short Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study
title_sort value of dynamic clinical and biomarker data for mortality risk prediction in covid-19: a multicentre retrospective cohort study
topic Research Methods
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513423/
https://www.ncbi.nlm.nih.gov/pubmed/32967887
http://dx.doi.org/10.1136/bmjopen-2020-041983
work_keys_str_mv AT berzuinicarlo valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy
AT hannancathal valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy
AT kingandrew valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy
AT vailandy valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy
AT olearyclaire valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy
AT broughdavid valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy
AT galeajames valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy
AT ogungbenrokayode valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy
AT wrightmegan valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy
AT pathmanabanomar valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy
AT hulmesharon valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy
AT allanstuart valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy
AT bernardinelliluisa valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy
AT patelhirenc valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy